Log in to search using one of your social media accounts:

 

Next Steps for Immunotherapies, Cell Therapies in Oncology Next Steps for Immunotherapies, Cell Therapies in Oncology

At ESMO 2017, Drs Zimmermann, Svane, and Coukos discuss successes and setbacks in immuno-oncology.Medscape Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Related Links:

LONDON (Reuters) - AstraZeneca's immunotherapy drug Imfinzi has won crucial approval from U.S. regulators for use in lung cancer, opening up a multibillion-dollar market for a medicine that has so far lagged behind competitors.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
The immunotherapy becomes the first treatment approved to reduce the risk for progression in hard-to-treat stage III non-small cell lung cancer.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
AbstractThe incidence of allergic conditions has continued to rise over the past several decades, with a growing body of research dedicated toward the treatment of such conditions. By driving a complex range of changes in the underlying immune response, immunotherapy is the only therapy that modulates the immune system with long-term effects and is presently utilized for the treatment of several atopic conditions. Recent efforts have focused on identifying biomarkers associated with these changes that may be of use in predicting patients with the highest likelihood of positive clinical outcomes during allergen immunotherap...
Source: Clinical Reviews in Allergy and Immunology - Category: Allergy & Immunology Source Type: research
The immunotherapy becomes the first treatment approved to reduce the risk for progression in hard-to-treat stage III non-small cell lung cancer.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
(Reuters) - The U.S. Food and Drug Administration on Friday granted approval for expanded use of AstraZeneca Plc's, immunotherapy drug, Imfinzi, to treat non-small cell lung cancer whose tumors can't be surgically removed.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
Authors: Mittal R, Jhaveri VM, McMurry HS, Kay SS, Sutherland KJ, Nicole L, Mittal J, Jayant RD Abstract Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality worldwide. Due to the significant impact of CVD on humans, there is a need to develop novel treatment modalities tailored to major classes of cardiac diseases including hypertension, coronary artery disease, cardiomyopathies, arrhythmias, valvular disease and inflammatory diseases. In this article, we discuss recent advancements regarding development of therapeutic strategies based on stem cells, aptamers, exosomes, drug-eluting and ...
Source: Artificial Cells, Nanomedicine and Biotechnology - Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research
The abscopal effect, whereby localized treatment to 1 tumor results in destruction of other untreated sites, is a rare phenomenon, described primarily in case reports. In melanoma, by combining treatments that augment the immune response with interventions (e.g., external-beam radiotherapy) that produce tumor antigens and danger signals from cell death, the abscopal effect can be triggered in as many as 25% of patients (1). In the context of metastatic breast cancer (MBC), abscopal effects have been reported in preclinical studies but not in human patients.
Source: Journal of Vascular and Interventional Radiology : JVIR - Category: Radiology Authors: Tags: Letter to the Editor Source Type: research
AbstractOur earlier studies reported a unique potentiated combination (TriCurin) of curcumin (C) with two other polyphenols. The TriCurin-associated C displays an IC50 in the low micromolar range for cultured HPV+  TC-1 cells. In contrast, because of rapid degradation in vivo, the TriCurin-associated C reaches only low nano-molar concentrations in the plasma, which are sub-lethal to tumor cells. Yet, injected TriCurin causes a dramatic suppression of tumors in TC-1 cell-implanted mice (TC-1 mice) and xenogr afts of Head and Neck Squamous Cell Carcinoma (HNSCC) cells innude/nude mice. Here, we use the TC-1 mice to te...
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
The therapeutic approach for the second-line treatment of patients with advanced non-small cell lung cancer (NSCLC) without actionable mutations has been revolutionized by the recent approval of new effective ...
Source: BMC Medicine - Category: Internal Medicine Authors: Tags: Commentary Source Type: research
AbstractPurpose of ReviewDuring the past few decades, modified allergens have been developed for use in allergen-specific immunotherapy (AIT) with the aim to improve efficacy and reduce adverse effects. This review aims to provide an overview of the different types of modified allergens, their mechanism of action and their potential for improving AIT.Recent FindingsIn-depth research in the field of allergen modifications as well as the advance of recombinant DNA technology have paved the way for improved diagnosis and research on human allergic diseases. A wide range of structurally modified allergens has been generated in...
Source: Current Allergy and Asthma Reports - Category: Allergy & Immunology Source Type: research
More News: Cancer & Oncology | Health | Hematology | Immunotherapy